Kaposiform hemangioendothelioma

Changed by Justin Rich, 8 Feb 2020

Updates to Article Attributes

Body was changed:

Kaposiform haemangioendothelioma is a rare, locally invasive vascular tumour that often presents in infancy, most commonly as an enlarging cutaneous mass. 

Epidemiology

Kaposiform haemangioendothelioma is a rare disease of childhood. The exact incidence and prevalence of has not been accurately determined, however the incidence and prevalencebut has been estimated to be 0.07 and 0.91 per 100,000 children per year, respectively, based on cases at a large referral center. Kaposiform haemangioendothelioma has no gender predilection and most commonly presents in the first year of life, however there area reports of development in later life. Genetic factors are thought to play a role in disease development but the exact cause has not been determined.

Clinical presentation

The majority of patients present with an enlarging cutaneous mass that may have red/purple cutaneous markings and telangiectasia. Other cutaneous presentations include erythematous plaques, patches or nodules. Non-cutaenous involvement can result in non-specific sympatomatology depending on the organs involved. Larger lesions, especially intrathoracic/intra-abdominal lesions may present with Kasabach-Merritt phenomenon, which is characterized by coagulopathy and thrombocytopenia caused by platelet trapping in the vascular tumour. Lesions are locally aggressive however the tumour is not known to metastasize.

Pathology

Kaposiform haemangioendotheliomas can occur anywhere in the body but have a predilection for the trunk and extremities. They most commonly present in subcutaneous tissue and tend to cross tissue planes involving fascia, muscle, bone and other structures.

Macroscopic

Kaposiform haemangioendotheliomas grossly appear as infiltrating nodules/masses. Sizes vary from small nodules or plaques to massive infiltrating tumours. Lesions often show a purple/red colouration. Intra-thoracic and intra-abdominal lesions tend to be larger and more infiltrative than peripheral lesions.

Microscopic

Characteristic histopathology shows spindle cells aligned in sheets or nodules forming vascular-like channels largely involving the subcutaneous tissues.

Markers

Immunohistochemistry shows positivity for CD31, CD34 and D2-40 (lymphatic marker).

Radiographic features

CT

Lesions show a homogenous mass with ill defined margins, often with extension into surrounding structures. Unenhanced CT often demonstates homogenous masses with iso-attenuation to adjuacent muscle, and heterogenous enhancement with contrast administration.

MRI

On T1-weighted images, lesions are hypointense and typically show poorly circumscribed soft tissue masses and diffuse enhancement with contrast.

Lesions are heterogenous, hyperintense masses on T2-weighted images, with heterogenous enhancement with contrast administration.

Ultrasound

Lesions are largely hyperechoic ill-defined masses with increased vascularity.

Treatment and prognosis

If patients are symptomatic and lesions are amenable to surgical resection, this remains the treatment option of choice and can be curative. Lesions that are asymptomatic and have no vital organ involvement may benefit from a period of observation, as spontaneous regression may occur without treatment.

In unresectable lesions with significant organ involvement or functional compromise, no current consensus exists for medical therapies. However the use of prednisolone along with anti-neoplastic and immunomodulatory agents (vincristine, sirolimus) is common.

Differential diagnosis

  • -<p><strong>Kaposiform haemangioendothelioma </strong>is a rare, locally invasive vascular tumour that often presents in infancy, most commonly as an enlarging cutaneous mass. </p><h4><strong>Epidemiology</strong></h4><p>Kaposiform haemangioendothelioma is a rare disease of childhood. The exact incidence and prevalence of has not been accurately determined, however the incidence and prevalence has been estimated to be 0.07 and 0.91 per 100,000 children per year, respectively, based on cases at a large referral center. Kaposiform haemangioendothelioma has no gender predilection and most commonly presents in the first year of life, however there area reports of development in later life. Genetic factors are thought to play a role in disease development but the exact cause has not been determined.</p><h4><strong>Clinical presentation</strong></h4><p>The majority of patients present with an enlarging cutaneous mass that may have red/purple cutaneous markings and telangiectasia. Other cutaneous presentations include erythematous plaques, patches or nodules. Non-cutaenous involvement can result in non-specific sympatomatology depending on the organs involved. Larger lesions, especially intrathoracic/intra-abdominal lesions may present with Kasabach-Merritt phenomenon, which is characterized by coagulopathy and thrombocytopenia caused by platelet trapping in the vascular tumour. Lesions are locally aggressive however the tumour is not known to metastasize.</p><h4><strong>Pathology</strong></h4><p>Kaposiform haemangioendotheliomas can occur anywhere in the body but have a predilection for the trunk and extremities. They most commonly present in subcutaneous tissue and tend to cross tissue planes involving fascia, muscle, bone and other structures.</p><h5>Macroscopic</h5><p>Kaposiform haemangioendotheliomas grossly appear as infiltrating nodules/masses. Sizes vary from small nodules or plaques to massive infiltrating tumours. Lesions often show a purple/red colouration. Intra-thoracic and intra-abdominal lesions tend to be larger and more infiltrative than peripheral lesions.</p><h5>Microscopic</h5><p>Characteristic histopathology shows spindle cells aligned in sheets or nodules forming vascular-like channels largely involving the subcutaneous tissues.</p><h5>Markers</h5><p>Immunohistochemistry shows positivity for CD31, CD34 and D2-40 (lymphatic marker).</p><h4><strong>Radiographic features</strong></h4><h5>CT</h5><p>Lesions show a homogenous mass with ill defined margins, often with extension into surrounding structures. Unenhanced CT often demonstates homogenous masses with iso-attenuation to adjuacent muscle, and heterogenous enhancement with contrast administration.</p><h5>MRI</h5><p>On T1-weighted images, lesions are hypointense and typically show poorly circumscribed soft tissue masses and diffuse enhancement with contrast.</p><p>Lesions are heterogenous, hyperintense masses on T2-weighted images, with heterogenous enhancement with contrast administration.</p><h5>Ultrasound</h5><p>Lesions are largely hyperechoic ill-defined masses with increased vascularity.</p><h4><strong>Treatment and prognosis</strong></h4><p>If patients are symptomatic and lesions are amenable to surgical resection, this remains the treatment option of choice and can be curative. Lesions that are asymptomatic and have no vital organ involvement may benefit from a period of observation, as spontaneous regression may occur without treatment.</p><p>In unresectable lesions with significant organ involvement or functional compromise, no current consensus exists for medical therapies. However the use of prednisolone along with anti-neoplastic and immunomodulatory agents (vincristine, sirolimus) is common.</p><h4><strong>Differential diagnosis</strong></h4><ul>
  • -<li>Infantile haemangiomas</li>
  • -<li>Congenital haemangiomas</li>
  • -<li>Kaposiform lymphangiomatosis</li>
  • +<p><strong>Kaposiform haemangioendothelioma </strong>is a rare, locally invasive vascular tumour that often presents in infancy, most commonly as an enlarging cutaneous mass. </p><h4><strong>Epidemiology</strong></h4><p>Kaposiform haemangioendothelioma is a rare disease of childhood. The exact incidence and prevalence has not been accurately determined, but has been estimated to be 0.07 and 0.91 per 100,000 children per year, respectively, based on cases at a large referral center. Kaposiform haemangioendothelioma has no gender predilection and most commonly presents in the first year of life, however there area reports of development in later life. Genetic factors are thought to play a role in disease development but the exact cause has not been determined.</p><h4><strong>Clinical presentation</strong></h4><p>The majority of patients present with an enlarging cutaneous mass that may have red/purple cutaneous markings and telangiectasia. Other cutaneous presentations include erythematous plaques, patches or nodules. Non-cutaenous involvement can result in non-specific sympatomatology depending on the organs involved. Larger lesions, especially intrathoracic/intra-abdominal lesions may present with Kasabach-Merritt phenomenon, which is characterized by coagulopathy and thrombocytopenia caused by platelet trapping in the vascular tumour. Lesions are locally aggressive however the tumour is not known to metastasize.</p><h4><strong>Pathology</strong></h4><p>Kaposiform haemangioendotheliomas can occur anywhere in the body but have a predilection for the trunk and extremities. They most commonly present in subcutaneous tissue and tend to cross tissue planes involving fascia, muscle, bone and other structures.</p><h5>Macroscopic</h5><p>Kaposiform haemangioendotheliomas grossly appear as infiltrating nodules/masses. Sizes vary from small nodules or plaques to massive infiltrating tumours. Lesions often show a purple/red colouration. Intra-thoracic and intra-abdominal lesions tend to be larger and more infiltrative than peripheral lesions.</p><h5>Microscopic</h5><p>Characteristic histopathology shows spindle cells aligned in sheets or nodules forming vascular-like channels largely involving the subcutaneous tissues.</p><h5>Markers</h5><p>Immunohistochemistry shows positivity for CD31, CD34 and D2-40 (lymphatic marker).</p><h4><strong>Radiographic features</strong></h4><h5>CT</h5><p>Lesions show a homogenous mass with ill defined margins, often with extension into surrounding structures. Unenhanced CT often demonstates homogenous masses with iso-attenuation to adjuacent muscle, and heterogenous enhancement with contrast administration.</p><h5>MRI</h5><p>On T1-weighted images, lesions are hypointense and typically show poorly circumscribed soft tissue masses and diffuse enhancement with contrast.</p><p>Lesions are heterogenous, hyperintense masses on T2-weighted images, with heterogenous enhancement with contrast administration.</p><h5>Ultrasound</h5><p>Lesions are largely hyperechoic ill-defined masses with increased vascularity.</p><h4><strong>Treatment and prognosis</strong></h4><p>If patients are symptomatic and lesions are amenable to surgical resection, this remains the treatment option of choice and can be curative. Lesions that are asymptomatic and have no vital organ involvement may benefit from a period of observation, as spontaneous regression may occur without treatment.</p><p>In unresectable lesions with significant organ involvement or functional compromise, no current consensus exists for medical therapies. However the use of prednisolone along with anti-neoplastic and immunomodulatory agents (vincristine, sirolimus) is common.</p><h4><strong>Differential diagnosis</strong></h4><ul>
  • +<li><a href="/articles/infantile-haemangioma">Infantile haemangiomas</a></li>
  • +<li><a href="/articles/congenital-haemangioma">Congenital haemangiomas</a></li>
  • +<li><a href="/articles/kaposiform-lymphangiomatosis-1">Kaposiform lymphangiomatosis</a></li>
  • -<li>Kaposi sarcoma</li>
  • +<li><a href="/articles/kaposi-sarcoma">Kaposi sarcoma</a></li>

References changed:

  • 1. Zukerberg L, Nickoloff B, Weiss S. Kaposiform Hemangioendothelioma of Infancy and Childhood. An Aggressive Neoplasm Associated with Kasabach-Merritt Syndrome and Lymphangiomatosis. Am J Surg Pathol. 1993;17(4):321-8. <a href="https://doi.org/10.1097/00000478-199304000-00001">doi:10.1097/00000478-199304000-00001</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/8494101">Pubmed</a>
  • 2. Croteau S, Liang M, Kozakewich H et al. Kaposiform Hemangioendothelioma: Atypical Features and Risks of Kasabach-Merritt Phenomenon in 107 Referrals. J Pediatr. 2013;162(1):142-7. <a href="https://doi.org/10.1016/j.jpeds.2012.06.044">doi:10.1016/j.jpeds.2012.06.044</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/22871490">Pubmed</a>
  • 11. Vivas-Colmenares G, Ramirez-Villar G, Bernabeu-Wittel J, Matute de Cardenas J, Fernandez-Pineda I. The Importance of Early Diagnosis and Treatment of Kaposiform Hemangioendothelioma Complicated by Kasabach-Merritt Phenomenon. Dermatol Pract Concept. 2015;5(1):91-3. <a href="https://doi.org/10.5826/dpc.050118">doi:10.5826/dpc.050118</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/25692091">Pubmed</a>
  • 5. Ji Y, Chen S, Peng S, Xia C, Li L. Kaposiform Lymphangiomatosis and Kaposiform Hemangioendothelioma: Similarities and Differences. Orphanet J Rare Dis. 2019;14(1):165. <a href="https://doi.org/10.1186/s13023-019-1147-9">doi:10.1186/s13023-019-1147-9</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/31277673">Pubmed</a>
  • 6. Hu P & Zhou Z. Clinical and Imaging features Of Kaposiform Hemangioendothelioma. Br J Radiol. 2018;91(1086):20170798. <a href="https://doi.org/10.1259/bjr.20170798">doi:10.1259/bjr.20170798</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/29536769">Pubmed</a>
  • 7. Ryu Y, Choi Y, Cheon J et al. Imaging Findings of Kaposiform Hemangioendothelioma in Children. Eur J Radiol. 2017;86:198-205. <a href="https://doi.org/10.1016/j.ejrad.2016.11.015">doi:10.1016/j.ejrad.2016.11.015</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/28027747">Pubmed</a>
  • 8. Mac-Moune Lai F, To K, Choi P et al. Kaposiform Hemangioendothelioma: Five Patients with Cutaneous Lesion and Long Follow-Up. Mod Pathol. 2001;14(11):1087-92. <a href="https://doi.org/10.1038/modpathol.3880441">doi:10.1038/modpathol.3880441</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/11706068">Pubmed</a>
  • 9. Drolet B, Trenor C, Brandão L et al. Consensus-Derived Practice Standards Plan for Complicated Kaposiform Hemangioendothelioma. J Pediatr. 2013;163(1):285-91. <a href="https://doi.org/10.1016/j.jpeds.2013.03.080">doi:10.1016/j.jpeds.2013.03.080</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/23796341">Pubmed</a>
  • 10. Chinello M, Di Carlo D, Olivieri F et al. Successful Management of Kaposiform Hemangioendothelioma with Long-Term Sirolimus Treatment: A Case Report and Review of the Literature. Mediterr J Hematol Infect Dis. 2018;10(1):e2018043. <a href="https://doi.org/10.4084/MJHID.2018.043">doi:10.4084/MJHID.2018.043</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/30002799">Pubmed</a>

Systems changed:

  • Paediatrics
  • Vascular

Updates to Primarylink Attributes

Title was added:
Kaposiform haemangioendothelioma
Type was set to PrimaryLink.
Content was set to .

Updates to Synonym Attributes

Title was added:
Kaposiform hemangioendothelioma
Type was set to Synonym.
Visible was set to .
Content was set to .

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.